semaglutide for cardiovascular GLP-1 agonists like Ozempic may reduce events by 20% Semaglutide dose may matter more
Description
Tirzepatide (Mounjaroand Zepbound), aGLP-1andGIPreceptor agonist, has recently gained significant popularity for itsweight loss benefits
Patients that stop taking Ozempic may regain weight, experience rising blood sugar, and lose other health benefits.
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Its important to talk with a healthcare provider about how long to use these medicines and make long-term healthy lifestyle changes to help keep weight off for good.What are the side effects?Common side effects include nausea, vomiting, diarrhea, abdominal pain, or constipation
